

NEWS RELEASE, 18 OCTOBER 2022

EVOTEC LAUNCHES PANOMICS DATA ANALYSIS PLATFORM PANHUNTER AT BIO-IT WORLD

- ▶ PANHUNTER EMPOWERS ANY SCIENTIST TO ACCESS AND ANALYSE DEEP BIOLOGICAL AND CLINICAL DATA INCLUDING IN PARTICULAR HUGE PANOMICS DATA SETS
- ▶ PANHUNTER ACCELERATES THE R&D PROCESS AND IMPROVES SUCCESS RATES

Hamburg, Germany, 18 October 2022:

Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) today announced the launch of the first commercial version of its PanOmics data analysis platform PanHunter at Bio-IT World (18-19 October in Berlin, Germany). PanHunter is Evotec's PanOmics data access and analytics platform and was developed and used successfully internally and in industry-shaping drug discovery partnerships over many years. Evotec now makes PanHunter available to collaborators and partners as a software-as-a-service ("SaaS") product.

PanHunter originates from Evotec's commitment towards patient-centric, PanOmics-driven drug discovery. The amount of available PanOmics data is growing at exponential rates in the public domain and in the pharmaceutical industry. More PanOmics data has been generated in the last two years than in all previous years combined. These PanOmics data hold an overwhelming amount of information about the condition of the respective patients, the molecular biological context, and causes of diseases. To extract such insights and new knowledge from data, it is paramount to use the smartest and easiest-to-use analytical tools and make them available to all scientists across disciplines.

PanHunter is unique in its ability to integrate the analysis of PanOmics data, designed as an easy-to-use yet fully comprehensive PanOmics data analysis platform. It thereby supports, for instance, the stratification of patient populations via molecular mechanisms and the prediction of efficacy and toxicity profiles of drug candidates given appropriate data inputs. With the launch of the first commercial version of the software at Bio-IT World Europe, Evotec makes PanHunter available to interested partners to accelerate their data-driven research.



Dr Cord Dohrmann, Chief Scientific Officer of Evotec, commented: "In the ever-accelerating world of Omics driven drug discovery we are excited to release PanHunter. PanHunter is our contribution to enable scientists to handle huge high-dimensional data sets to better understand diseases on a molecular level. Improved molecular understanding of disease as well as drug candidates accelerates the drug discovery process and improves probabilities of success in the pre-clinic and clinic."

Dr Matthias Evers, Chief Business Officer of Evotec, said: "With our first commercial release, we are making a bold claim that the future of successful drug discovery lies in convergence between science and tech. With PanHunter we enable scientists across disciplines to explore this potential and engage in patient-driven, PanOmics-informed drug discovery towards deep disease understanding and achieving tractable insights. It is another step to overcome the limitations of a reductionist R&D approach and use AI to unleash disease understanding and improve success rates ("POS")."


For further information, please <u>follow this link</u> to the PanHunter website or contact us via <u>panhunter@evotec.com</u>. To continue reading, <u>follow this link</u> to our latest DDup edition on PanHunter, including user interviews and case studies.

ABOUT EVOTEC SE

Evotec is a life science company with a unique business model that delivers on its mission to discover and develop highly effective therapeutics and make them available to the patients. The Company's multimodality platform comprises a unique combination of innovative technologies, data and science for the discovery, development, and production of first-in-class and best-in-class pharmaceutical products. Evotec leverages this "Data-driven R&D Autobahn to Cures" for proprietary projects and within a network of partners including all Top 20 Pharma and over 800 biotechnology companies, academic institutions, as well as other healthcare stakeholders. Evotec has strategic activities in a broad range of currently underserved therapeutic areas, including e.g. neurology, oncology, as well as metabolic and infectious diseases. Within these areas of expertise, Evotec aims to create the world-leading co-owned pipeline for innovative therapeutics and has to-date established a portfolio of more than 200 proprietary and co-owned R&D projects from early discovery to clinical development. Evotec operates globally with more than 4,500 highly qualified people. The Company's 16 sites offer highly synergistic technologies and services and operate as complementary clusters of excellence. For additional information please go to www.evotec.com and follow us on Twitter @Evotec and LinkedIn.

FORWARD-LOOKING STATEMENTS

This announcement contains forward-looking statements concerning future events, including the proposed offering and listing of Evotec's securities. Words such as "anticipate," "believe," "could," "estimate," "expect," "intend," "may," "might," "plan," "potential," "should," "target," "would" and variations of such words and similar expressions are intended to identify forward-looking statements. Such statements include comments regarding Evotec's expectations for revenues, Group EBITDA and unpartnered R&D expenses. These forward-looking statements are based on the information available to, and the expectations and assumptions deemed reasonable by Evotec at the time these statements were made. No assurance can be given that such expectations will prove to have been correct. These statements involve known and unknown risks and are based upon a number of assumptions and estimates, which are inherently subject to significant uncertainties and contingencies, many of which are beyond the control of Evotec. Evotec expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking



statements contained herein to reflect any change in Evotec's expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.